-
Mashup Score: 0CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma - 2 year(s) ago
Abstract. To address antigen escape and loss of T-cell functionality, we report a phase-1 clinical trial (NCT04007029) evaluating autologous naive and memory T (TN/MEM) cells engineered to express a bispecific anti-CD19/CD20 CAR (CART19/20) for patients with relapsed/refractory NHL, with safety as the primary end point. Ten patients were treated with 36–165 x 106 CART19/20 cells. No patient…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Dimas - Non-Hodgkin Lymphoma - 2 year(s) ago
Striking out non-Hodgkin Lymphoma Non-Hodgkin Lymphoma Dimas’s Story Dimas has been following his dreams his entire life. As a child, he wanted to be a professional baseball player. He worked hard and was drafted by the LA Dodgers as a pitcher. After a rotator cuff injury ended his professional baseball career, he…
Source: CRISPRCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0VJHemOnc – The video journal of hematological oncology - 2 year(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Newsletter | VJHemOnc - 2 year(s) ago
Email * Institute/Organization * Country * VJHemOnc is intended for Healthcare Professionals onlyWhat is your primary role? * Please select the areas you are interested in: All DiseasesLeukemiasLymphomasMultiple MyelomaMPNsMDSOther DiseasesVJHemOnc uses the above contact information to keep you up to date with our latest hemonc news and videos. Emails and website content are sometimes supported…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Newsletter | VJHemOnc - 2 year(s) ago
Email * Institute/Organization * Country * VJHemOnc is intended for Healthcare Professionals onlyWhat is your primary role? * Please select the areas you are interested in: All DiseasesLeukemiasLymphomasMultiple MyelomaMPNsMDSOther DiseasesVJHemOnc uses the above contact information to keep you up to date with our latest hemonc news and videos. Emails and website content are sometimes supported…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJHemOnc – The video journal of hematological oncology - 2 year(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Acute Kidney Injury After CAR-T Therapy for Non-Hodgkin Lymphoma - 2 year(s) ago
Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1CAR-T therapy in myeloma and lymphoma - 2 year(s) ago
CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1The current state of CAR-T therapy in lymphoma - 2 year(s) ago
Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Non-Hodgkin Lymphoma - Cancer Stat Facts - 2 year(s) ago
Non-Hodgkin Lymphoma statistics
Source: SEERCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory #TCells for the Treatment of Relapsed or Refractory #NonHodgkinLymphoma, by Sarah Larson, Yvonne Chen et al. https://t.co/lCXNKOr9jy @UCLAJCCC @dgsomucla @UCLA https://t.co/mmvWvxLY76